Latest Insider Transactions at Biora Therapeutics, Inc. (BIOR)
This section provides a real-time view of insider transactions for Biora Therapeutics, Inc. (BIOR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIORA THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIORA THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2022
|
Jeffrey D. Alter |
BUY
Grant, award, or other acquisition
|
Direct |
96,154
+37.01%
|
-
|
|
Jun 15
2022
|
Jill Ann Howe |
BUY
Grant, award, or other acquisition
|
Direct |
96,154
+35.74%
|
-
|
|
Jun 15
2022
|
Brian L. Kotzin |
BUY
Grant, award, or other acquisition
|
Direct |
96,154
+40.09%
|
-
|
|
May 15
2022
|
Eric D Esparbes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
292,406
+29.31%
|
-
|
|
May 15
2022
|
Eric D Esparbes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,387
-2.45%
|
$0
$0.75 P/Share
|
|
May 15
2022
|
Aditya P. Mohanty Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,562,500
+34.44%
|
-
|
|
May 15
2022
|
Clarke Neumann |
BUY
Grant, award, or other acquisition
|
Direct |
239,962
+30.44%
|
-
|
|
May 15
2022
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
8,305
-2.62%
|
$0
$0.75 P/Share
|
|
Apr 15
2022
|
Clarke Neumann |
BUY
Grant, award, or other acquisition
|
Direct |
184,843
+36.86%
|
-
|
|
Apr 15
2022
|
Eric D Esparbes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
231,693
+35.38%
|
-
|
|
Feb 15
2022
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
1,716
-1.29%
|
$1,716
$1.9 P/Share
|
|
Feb 15
2022
|
Hutan Hashemi Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
187
-0.65%
|
$187
$1.9 P/Share
|
|
Feb 15
2022
|
Eric D Esparbes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,919
-2.5%
|
$4,919
$1.9 P/Share
|
|
Nov 15
2021
|
Damon Silvestry Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,566
-1.54%
|
$13,698
$3.47 P/Share
|
|
Nov 15
2021
|
Matthew T Cooper General Manager, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
700
-0.52%
|
$2,100
$3.47 P/Share
|
|
Nov 15
2021
|
Hutan Hashemi Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
645
-2.2%
|
$1,935
$3.47 P/Share
|
|
Nov 15
2021
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-0.56%
|
$2,256
$3.47 P/Share
|
|
Nov 08
2021
|
Aditya P. Mohanty Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,412,429
+50.0%
|
-
|
|
Nov 03
2021
|
Jill Ann Howe |
BUY
Grant, award, or other acquisition
|
Direct |
76,754
+50.0%
|
-
|
|
Aug 15
2021
|
Matthew T Cooper General Manager, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
560
-0.44%
|
$560
$1.66 P/Share
|
|
Aug 15
2021
|
Eric D Esparbes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,718
-2.83%
|
$5,718
$1.66 P/Share
|
|
Aug 15
2021
|
Hutan Hashemi Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-0.7%
|
$158
$1.66 P/Share
|
|
Aug 15
2021
|
Harry Stylli Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,335
-0.07%
|
$10,335
$1.66 P/Share
|
|
Aug 15
2021
|
Damon Silvestry Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,478
-0.51%
|
$1,478
$1.66 P/Share
|
|
Aug 15
2021
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
2,336
-1.71%
|
$2,336
$1.66 P/Share
|
|
Aug 06
2021
|
Troy Seelye Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,673
-28.38%
|
$23,673
$1.94 P/Share
|
|
Jul 01
2021
|
Surbhi Sarna Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,137
+50.0%
|
-
|
|
Jun 14
2021
|
Jeffrey D. Alter |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+30.18%
|
-
|
|
Jun 14
2021
|
John T. Bigalke Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+38.05%
|
-
|
|
Jun 14
2021
|
Brian L. Kotzin |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+38.05%
|
-
|
|
Jun 14
2021
|
Samuel R Md Nussbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+38.05%
|
-
|
|
Jun 14
2021
|
Lynne Powell |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+38.05%
|
-
|
|
Jun 14
2021
|
Athyrium Opportunities Fund (A) LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,097,166
+18.2%
|
$16,194,332
$2.47 P/Share
|
|
Jun 14
2021
|
Athyrium Capital Management, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,097,166
+18.2%
|
$16,194,332
$2.47 P/Share
|
|
Jun 01
2021
|
Athyrium Opportunities Fund (A) LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,268,115
+2.18%
|
$2,536,230
$2.86 P/Share
|
|
Jun 01
2021
|
Athyrium Capital Management, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,268,115
+2.18%
|
$2,536,230
$2.86 P/Share
|
|
May 15
2021
|
Matthew T Cooper General Manager, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,400
-1.08%
|
$2,800
$2.36 P/Share
|
|
May 15
2021
|
Hutan Hashemi Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
69
-0.3%
|
$138
$2.36 P/Share
|
|
May 15
2021
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
1,505
-1.09%
|
$3,010
$2.36 P/Share
|
|
May 15
2021
|
Troy Seelye Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,925
-2.26%
|
$3,850
$2.36 P/Share
|
|
May 15
2021
|
Sami Shihabi Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
840
-0.66%
|
$1,680
$2.36 P/Share
|
|
Apr 15
2021
|
Harry Stylli Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
229,885
+1.53%
|
-
|
|
Apr 15
2021
|
Matthew T Cooper General Manager, Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
80,460
+38.26%
|
-
|
|
Apr 15
2021
|
Eric D Esparbes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,690
-6.34%
|
$41,070
$3.41 P/Share
|
|
Apr 15
2021
|
Eric D Esparbes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
123,382
+36.38%
|
-
|
|
Apr 15
2021
|
Hutan Hashemi Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,494
+50.0%
|
-
|
|
Apr 15
2021
|
Clarke Neumann |
BUY
Grant, award, or other acquisition
|
Direct |
87,356
+38.75%
|
-
|
|
Apr 15
2021
|
Troy Seelye Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,231
-6.8%
|
$18,693
$3.41 P/Share
|
|
Apr 15
2021
|
Troy Seelye Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,836
+37.45%
|
-
|
|
Apr 15
2021
|
Sami Shihabi Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,954
+41.99%
|
-
|